The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice

Megumi Akamatsu¹,², *, Takenari Yamashita¹,², *, Naoki Hirose¹,², Sayaka Teramoto¹,² & Shin Kwak¹,³

Both TDP-43 pathology and failure of RNA editing of AMPA receptor subunit GluA2, are etiology-linked molecular abnormalities that concomitantly occur in the motor neurons of the majority of patients with amyotrophic lateral sclerosis (ALS). AR2 mice, in which an RNA editing enzyme adenosine deaminase acting on RNA 2 (ADAR2) is conditionally knocked out in the motor neurons, exhibit a progressive ALS phenotype with TDP-43 pathology in the motor neurons through a Ca²⁺-permeable AMPA receptor-mediated mechanism. Therefore, amelioration of the increased Ca²⁺ influx by AMPA receptor antagonists may be a potential ALS therapy. Here, we showed that orally administered perampanel, a selective, non-competitive AMPA receptor antagonist significantly prevented the progression of the ALS phenotype and normalized the TDP-43 pathology-associated death of motor neurons in the AR2 mice. Given that perampanel is an approved anti-epileptic drug, perampanel is a potential candidate ALS drug worthy of a clinical trial.

Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease, characterized by the progressive loss of both upper and lower motor neurons. Patients with ALS die from progressive respiratory muscle paralysis within a few years after disease onset, but therapies that effectively alter the disease course are not currently available. Although more than 30 ALS-linked genes, including the Cu/Zn superoxide dismutase (SOD1) gene, have been identified¹, most of the sporadic ALS patients that account for the great majority of all the ALS patients do not carry mutations in these ALS-linked genes. The candidate drugs that have been developed to treat ALS are largely based on studies in SOD1 transgenic mice ²–⁴, the most widely used ALS animal model, but virtually all of these drugs have proven ineffective ⁵–⁷. Therefore, a novel strategy for drug development that exploits evaluation markers that are closely linked with ALS pathogenesis would be valuable.

TAR DNA-binding protein 43 (TDP-43) pathology, which is characterized by the mislocalization of TDP-43 from the nucleus to abnormal cytoplasmic inclusion bodies in motor neurons ⁸,⁹, is observed in the motor neurons of ALS patients. The mechanism underlying the generation of TDP-43 pathology, although not yet fully elucidated, is believed to be closely involved in the ALS pathogenesis. Normalization of TDP-43 pathology could therefore be a reliable marker for therapeutic efficacy, but the motor neurons of SOD1 transgenic mice do not exhibit typical TDP-43 pathology ³–⁴.

In addition to TDP-43 pathology ⁵,⁶, RNA editing failure at the glutamine/arginine (Q/R) site of GluA2, an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor subunit, is observed in the motor neurons of the majority of patients with sporadic ALS in a disease-specific manner ¹¹–¹₄. Adenosine deaminase acting on RNA 2 (ADAR2) specifically catalyzes RNA editing at the Q/R site of GluA2, and its expression is downregulated ¹⁵–¹⁷ in sporadic ALS. Therefore, a novel strategy for drug development that exploits evaluation markers that are closely linked with ALS pathogenesis would be valuable.

¹Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan. ²Department of Neuropathology, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan. ³Clinical Research Center for Medicine, International University of Health and Welfare, Ichikawa, Chiba, Japan. ⁴These authors contributed equally to this work. Correspondence and requests for materials should be addressed to S.K. (email: kwak-tky@umin.ac.jp)
in the ALS motor neurons. Consistently, in ALS patients, motor neurons that exhibited cytoplasmic inclusions positive for phosphorylated TDP-43 or other patterns of TDP-43 pathology were invariably devoid of ADAR2 immunoreactivity. Conditional ADAR2 knockout mice (ADAR2<sup>ΔADAR2</sup>YAC<sup>ΔADAR2</sup>-Cre<sup>Fast</sup>; AR2) exhibit a progressive ALS phenotype resulting from the death of motor neurons due to ADAR2-downregulation, and notably exhibit mislocalization of TDP-43 from the nucleus to the cytoplasm in the ADAR2-lacking motor neurons. These lines of evidence indicate that a Ca<sup>2+</sup>-permeable AMPA receptor-mediated mechanism similar to the mechanism that takes place in AR2 mice likely also occurs in the motor neurons of ALS patients. Furthermore, normalization of Ca<sup>2+</sup> influx through the AMPA receptors, including expression of Q/R site-edited GluA2 in the absence of ADAR2 or delivery of the human ADAR2 gene for normalizing RNA editing at the GluA2 Q/R site, effectively rescued the ALS phenotype and death of motor neurons associated with the TDP-43 mislocalization in the AR2 mice. Therefore, the exaggerated Ca<sup>2+</sup> influx through the abnormal AMPA receptors could be a therapeutic target for sporadic ALS, and the normalization of TDP-43 mislocalization in AR2 mice could serve as a reliable marker to evaluate the efficacy of newly developed treatments.

**Results**

**Perampanel prevented the death of motor neurons and normalized TDP-43 subcellular localization in AR2 and AR2H mice.** We first administered perampanel to homozygous (AR2)<sup>ΔADAR2</sup> and heterozygous (AR2H)<sup>ΔADAR2</sup> conditional ADAR2 knockout mice at 17 weeks of age. The perampanel was delivered orally every 14 days; methyl cellulose (vehicle) was used as a control. The mice were akinetic for several hours following the administration, but the duration of the sedative phase became increasingly shorter with time, and all of the mice tolerated the 14-day administration of perampanel at dosages below 20 mg/kg/day. At 19 weeks of age, the number of TO-PRO-3-positive anterior horn cells (AHCs; diameter ≥20 μm) in the 5th lumbar spinal cord (L5) was significantly lower in the vehicle-treated AR2 mice (48.2 ± 1.3, mean ± s.e.m.) than in the AR2H mice (57.7 ± 1.3) and the wild-type (WT) mice (63.5 ± 0.8) (Fig. 1a), in accordance with the results observed for the non-treated AR2 mice. In the AR2H mice, perampanel significantly increased the total number of AHCs at dosages greater than 13.2 mg/kg/day (Fig. 1a) and of TDP-43-positive AHCs at dosages greater than 6.6 mg/kg/day, and these increases occurred in a dose-dependent manner (Fig. 1b). In the AR2 mice, perampanel at a dosage of 13.2 mg/kg/day significantly increased the number of TDP-43-positive AHCs but not the total number of AHCs (Fig. 1b). When the TDP-43-positive AHCs were classified according to the subcellular distribution of TDP-43 (Fig. 1c), the number of AHCs with nucleocytoplasmic and/or cytoplasmic TDP-43 was significantly increased by the perampanel treatment at dosages greater than 13.2 mg/kg/day (Fig. 1d).

**Amelioration of motor dysfunction by long-term administration of perampanel to AR2 mice.** To test the efficacy of perampanel on the ALS phenotype, we next orally administered perampanel every day for 90 days to AR2 mice at 26–28 weeks of age, a time when the majority of AR2 mice already exhibit motor dysfunction. To avoid excessive sedation upon treatment initiation, perampanel was first administered at a dose of 13.2 mg/kg for 4 days and then at 20 mg/kg for the remaining 86 days; methyl cellulose (vehicle) was used as a control. All of the mice were tested for rotarod retention time and grip strength once a week throughout the experiment, beginning several weeks before the first perampanel administration. The perampanel-treated AR2 mice did not gain weight (Fig. 2b) but were behaviorally active and displayed a constant rotarod score (Fig. 2c). As expected, perampanel increased the number of AHCs (Fig. 2a) and grip strength (Fig. 2d) throughout the experiment, which were significantly better than the vehicle-treated mice did not gain weight (Fig. 2b) but were behaviorally active and displayed a constant rotarod score (Fig. 2c). To avoid excessive sedation upon treatment initiation, perampanel was first administered at a dose of 13.2 mg/kg for 4 days and then at 20 mg/kg for the remaining 86 days; methyl cellulose (vehicle) was used as a control. All of the mice were tested for rotarod retention time and grip strength once a week throughout the experiment, beginning several weeks before the first perampanel administration. The perampanel-treated AR2 mice did not gain weight (Fig. 2b) but were behaviorally active and displayed a constant rotarod score (Fig. 2c) and grip strength (Fig. 2d) throughout the experiment, which were significantly better than the vehicle-treated AR2 mice. All of the mice tolerated the 90-day administration of perampanel.

**Long-term administration of perampanel rescued AHCs from death and normalized TDP-43 subcellular localization.** When the spinal cords were histologically evaluated, the number of AHCs in the perampanel-treated AR2 mice (64.2 ± 3.0) was significantly greater than that in the vehicle-treated mice (35.2 ± 1.8, Fig. 3a). TO-PRO-3 was used as a cell marker in our experiments. In the AR2 mice, perampanel administration also shifted the peak of the histogram of AHC diameter from the range of 25–29 μm to that of 30–34 μm and increased the proportion of AHCs with a diameter greater than 30 μm compared to the vehicle-treated AR2 mice (Fig. 3b). The frequency histogram of AHC diameter revealed that perampanel restored the size of AHCs in the AR2 mice to a level equivalent to that of AHCs in the age-matched WT mice (Supplementary Fig. 1). The number of TDP-43-positive AHCs was also increased in the perampanel-treated AR2 mice (Fig. 3c,d), particularly those that were TDP-43-positive in both the nucleus and cytoplasm (Fig. 3c,e). Furthermore, most of the TDP-43-positive AHCs in the vehicle-treated AR2 mice exhibited focal cytoplasmic TDP-43-positive aggregates or inclusions (asterisk in Fig. 3c) rather than the diffuse cytoplasmic positivity observed in the TDP-43-positive AHCs in the perampanel-treated AR2 mice (Fig. 3c).

**Discussion**

Present results showed that oral administration of perampanel, a selective, non-competitive AMPA receptor antagonist, to the AR2H and AR2 mice for 14 days effectively normalized TDP-43 pathology in motor neurons and that its administration for 90 days significantly prevented the progression of the ALS phenotype and the TDP-43 pathology-associated death of motor neurons. Success in the rescue of ALS phenotype of the AR2 mice, a mechanistic mouse model of sporadic ALS, indicates that perampanel is a potential candidate ALS drug.

Perampanel is a novel AMPA receptor antagonist that inhibits the excitation of postsynaptic membranes by selectively attenuating calcium influx through AMPA receptors. As expected, perampanel increased the number of TDP-43-positive AHCs in the AR2 mice (Figs 1b and 3d). TDP-43 immunoreactivity was observed virtually exclusively in the nucleus in the normal motor neurons of WT mice, whereas it mislocalized in the cytoplasm or was absent in the motor neurons that expressed Q/R site-unedited GluA2 in the AR2 mice. This mislocalization of TDP-43 was caused by abnormal and continuous activation of Ca<sup>2+</sup>-dependent protease calpain and...
normalization of Ca²⁺ influx through the AMPA receptors restored TDP-43 mislocalization in the AR2 mice. In the present study, we found three different patterns of subcellular localization of TDP-43 in the AR2 mouse motor neurons; nuclear, nucleocytoplasmic, and cytoplasmic. A previous study has shown that these different subcellular distribution patterns of TDP-43 immunoreactivity likely reflected different levels of cytoplasmic Ca²⁺ concentrations in the motor neurons; higher in the cytoplasmic pattern than in the nucleocytoplasmic pattern, and normal in the nuclear pattern. The present results demonstrating the increase in the number of TDP-43-positive neurons, particularly those with nuclear and nucleocytoplasmic patterns (Figs 1d and 3e) suggest that perampanel may have ameliorated the increased Ca²⁺ influx that occurred in the ADAR2-lacking motor neurons in the AR2 mice.

In addition, perampanel, and not vehicle, restored the size of AHCs to the level observed in age-matched WT mice (Fig. 3b); this effect likely reflects the restoration of physiological functions that were disturbed by the increased Ca²⁺ influx through the abnormal AMPA receptors. Notably, perampanel was effective not only in asymptomatic AR2 mice but also in AR2 mice during the progression of the disease, as observed in the study of adeno-associated virus-mediated delivery of the ADAR2 gene. The robust protective effects of perampanel on ADAR2-lacking motor neurons in AR2 mice suggest that perampanel may have ameliorated the increased Ca²⁺ influx that occurred in the ADAR2-lacking motor neurons in the AR2 mice.

In addition, perampanel, and not vehicle, restored the size of AHCs to the level observed in age-matched WT mice (Fig. 3b); this effect likely reflects the restoration of physiological functions that were disturbed by the increased Ca²⁺ influx through the abnormal AMPA receptors. Notably, perampanel was effective not only in asymptomatic AR2 mice but also in AR2 mice during the progression of the disease, as observed in the study of adeno-associated virus-mediated delivery of the ADAR2 gene. The robust protective effects of perampanel on ADAR2-lacking motor neurons in AR2 mice suggest that perampanel would be even more effective in preventing excess Ca²⁺ influx in the motor neurons of ALS patients because ALS AHCs maintain ADAR2 activity to some extent. The perampanel-treated AR2 mice failed to gain body weight but were physically active and exhibited better motor function scores than the vehicle-treated AR2 mice (Fig. 2). Because the loss of body weight has not been reported as an adverse effect of perampanel in clinical trials, the lack of body weight gain in the perampanel-treated AR2 mice might have resulted from the preservation of physical activity rather than any adverse effects of perampanel.
Excitotoxicity has been proposed to underlie ALS pathogenesis, and AMPA receptor antagonists are believed to have potential as a treatment for ALS. Indeed, the AMPA receptor antagonist talampanel was initially found to be beneficial for ALS patients in a phase II clinical trial, but unfortunately, the phase III clinical trial was not extended due to insufficient efficacy. Both talampanel and perampanel are non-competitive AMPA receptor antagonists, but compared to talampanel, perampanel has a much longer terminal half-life in humans (approximately 105 hours) than talampanel (approximately 3–4 hours). Furthermore, perampanel has been approved in over 40 countries as an adjunctive therapy for the treatment of partial seizures with or without secondary generalization. The long half-life and safety of perampanel render it a promising ALS drug.

Recently, failure of GluA2 Q/R site-editing has been demonstrated in the motor neurons of an ALS patient with FUS P525L mutation and in the pathological tissues of ALS patients carrying the C9ORF72 gene with hexanucleotide repeat expansion, suggesting that efficacy of perampanel would be expected in some form of familial ALS patients, as well. We believe that the present results provide a rationale for clinical trials of perampanel in ALS patients.

**Methods**

**Animals.** Homozygous (ADAR2floxflox/VACHT-Cre.Fast; AR2) and heterozygous (ADAR2flox/+ /VACHT-Cre. Fast; AR2H) conditional ADAR2 knockout mice were used in this study. In these mice, Cre is selectively expressed in motor neurons under the control of the vesicular acetylcholine transporter promoter, ablating the ADAR2 gene in approximately 50% of motor neurons by the age of five postnatal weeks. As a result, 100% and no more than 30% of GluA2 is unedited at the Q/R site in the motor neurons of AR2 and AR2H mice, respectively. In these mice, the expression of GluA2 that is unedited at the Q/R site results in the slowly progressive death of motor neurons via Ca²⁺-permeable AMPA receptor-mediated mechanisms. Both genders of AR2 and AR2H mice were used in this study. C57BL/6j mice were also used as the WT control of the same strain. The mice were housed at two to three per cage on a 12h:12h light-dark cycle with free access to food and water. All of the studies were approved by the Committee on Animal Handling at the University of Tokyo and were performed in accordance with the guidelines for animal experiments of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Perampanel treatment. Perampanel powder, which was provided by Eisai Co., Ltd., was suspended in a 0.5% W/V methyl cellulose (400 cP, W AKO) solution, and a volume of 4 μl per g of body weight was administered daily to the mice via oral gavage (p. o.). For the 14-day administration, 17-week-old mice received either 3.3, 6.6, 13.2 or 20 mg/kg (n = 5, 8, 5, and 6 AR2H mice, respectively) or 13.2 mg/kg (n = 5, AR2 mice) perampanel. For the 90-day administration, perampanel was administered to AR2 mice (26–28 weeks of age) at a dosage of 13.2 mg/kg/day for the first four days and then at 20 mg/kg/day for the remaining 86 days (n = 8). The control mice, AR2H (n = 7) and AR2 (n = 5) for the 14-day administration and AR2 (n = 7) for the 90-day administration, received oral gavage of the same volume of a 0.5% methyl cellulose solution for the same period.

Performance analyses. Rotarod task. The mice were placed on a rotarod (Muromachi Kikai Co. LTD MK-610A), the speed of which linearly accelerated from four rpm to 40 rpm over 240 seconds. The maximum latency to fall from the rod out of three runs was recorded. The mice used in this study were well trained on the rotarod task prior to drug administration. Grip strength. The mice were held by their tails by the researcher and allowed to grasp the steel grip of the baseplate of a Grip Strength Meter (GSM) with their forepaws. The mice were then gently pulled backward until they released the steel grip. The average power (N) at the time of grip release of three trials was recorded. All behavioral measurements were conducted weekly by a researcher who was blinded to the drug administration information.

Antibodies. The primary antibody included rabbit anti-TDP-43 (10782-2AP, ProteinTech Group, Inc.), while the secondary antibodies included Alexa Fluor 488 chicken anti-rabbit IgG (A21441, Invitrogen).

Reagents. Perampanel was obtained from Eisai Co., Ltd., methyl cellulose (400 cP) was purchased from WAKO, and TO-PRO-3 was purchased from lifetechnologies.
**Immunohistochemistry.** Three hours after the last oral gavage administration, the brains and spinal cords of the mice were extracted under deep isoflurane anesthesia, incubated with 3.5% paraformaldehyde and 0.5% glutaraldehyde in phosphate-buffered saline (PBS) at 4°C overnight and then immersed in a graded series of sucrose-PBS solutions (from 10% to 30% final sucrose concentration) at 4°C. Ten-μm-thick serial sections were cut with a cryostat (Model LEICA CM1850; Leica), blocked with 10% skim milk in PBS, and incubated overnight at 4°C with the rabbit anti-TDP-43 (ProteinTech Group, Inc., 1:200) primary antibody. The sections were then incubated with the Alexa Fluor 488 chicken anti-rabbit IgG (Invitrogen, 1:200 in PBS) secondary antibody for one hour at room temperature. Cell staining was performed with 0.5 μM TO-PRO-3. Immunostaining images were captured using a BIORÉVO BZ-9000 fluorescence microscope (KEYENCE Co., Ltd.), and the number of cells with a diameter of ≥20 μm in the anterior horns (AHCs) was quantified in three sections per animal using ImageJ software (NIH). The immunoreactive signal intensity was analyzed with ImageJ software, with a grayscale background intensity of less than 20 (11.6 ± 0.55; mean ± s.e.m., max 19.9 gray). TDP-43 positivity was defined as an intensity threefold greater (≥60 gray) than that of the background intensity. The TDP-43 distribution pattern was classified as predominantly nuclear (N), cytoplasmic (C) or nucleo-cytoplasmic (N/C).

**Statistical analyses.** Average data are presented as the mean and s.e.m. Statistical analyses were conducted using JMP 9 software (SAS Institute, Inc.). For statistical comparisons of two groups, we used the Wilcoxon rank sum test. Multi-group data were analyzed using one-way ANOVA followed by Tukey post hoc tests. Differences were considered significant when p < 0.05.

**References**

1. Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S. A., Goutman, S. A. & Feldman, E. L. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. *Nature reviews. Neurology* 11, 266–279 (2015).

2. Jonson, P. A. et al. Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase 1. *Journal of neuropathology and experimental neurology* 65, 1126–1136 (2006).

3. Joyce, P. I., Fratta, P., Fisher, E. M. & Acevedo-Arozena, A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. *Mammalian genome: official journal of the International Mammalian Genome Society* 22, 420–448 (2011).

4. Reaume, A. G. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. *Nature genetics* 13, 43–47 (1996).

5. Goyal, N. A. & Mozaffar, T. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. *Expert opinion on investigational drugs* 23, 1541–1551 (2014).

6. Berry, J. D. et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. *PloS one* 8, e61777 (2013).

7. Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally in patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. *The Lancet. Neurology* 12, 435–442 (2013).

8. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem. Biophys. Res. Commun.* 351, 602–611 (2006).

9. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science (New York, N.Y.)* 314, 130–133 (2006).

10. Tsao, W. et al. Rodent models of TDP-43: recent advances. *Brain research* 1462, 26–39 (2012).

11. Takuma, H., Kwak, S., Yoshizawa, T. & Kanazawa, I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. *Ann Neurol* 46, 806–815 (1999).

12. Kawahara, Y. et al. Glutamate receptors: RNA editing and death of motor neurons. *Nature* 229, 111–113 (1981).

13. Kawahara, Y. & Kwak, S. Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? *Amyotrophic Lateral Scler Other Motor Neuron Disord* 6, 131–144 (2005).

14. Hideyama, Y. et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. *Neurobiol Dis* 45, 1121–1128 (2012).

15. Melcher, T. et al. A mammalian RNA editing enzyme. *Nature* 379, 460–464 (1996).

16. Gerber, A., O’Connell, M. A. & Keller, W. Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. *Proc. Natl. Acad. Sci. USA* 94, 120–124 (1997).

17. Yamashita, T. et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons of sporadic amyotrophic lateral sclerosis patients. *EMBO Mol Med* 5, 1710–1719 (2013).

18. Aizawa, H. et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. *Acta Neuropathol* 120, 75–84 (2010).

19. Hideyama, Y. et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. *J Neurosci* 30, 11917–11925 (2010).

20. Hideyama, Y. & Kwak, S. When Does ALS Start? ADAR2–GluA2 Hypothesis for the Etiology of Sporadic ALS. *Front Mol Neurosci* 4, 33 (2011).

21. Yamashita, T. et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. *Nat Commun* 3, 1307 (2012).

22. Yamashita, T. & Kwak, S. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. *Brain research* 1584, 28–38 (2014).

23. Yamashita, T. et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9–ADAR2 delivery to motor neurons. *Acta Neurol Scand. Suppl.* 194–20 (2013).

24. Shao, C. Y., Mirra, S. S., Sait, H. B., Saktor, T. C. & Sigurdsson, E. M. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer’s disease. *Acta Neuropathol* 122, 285–292 (2011).

25. Hideyama, Y., Teramoto, S., Hachiga, K., Yamashita, T. & Kwak, S. Co-Occurrence of TDP-43 Mislocalization with Reduced Activity of an RNA Editing Enzyme, ADAR2, in Aged Mouse Motor Neurons. *PloS one* 7, e43469 (2012).

26. Hanada, T. et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. *Epilepsia* 52, 1331–1340 (2011).

27. Rogawski, M. A. & Hanada, T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. *Acta Neurol. Scand. Suppl.* 194–20 (2013).

28. Hanada, T. The discovery and development of perampanel for the treatment of epilepsy. *Expert Opin. Drug Discov.* 9, 449–458 (2014).
29. Howes, J. F. & Bell, C. Talampanel. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 4, 126–129 (2007).
30. Pascuzzi, R. M. et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 11, 266–271 (2010).
31. ALS ASSOCIATION-Talampanel Trial Concluded with Negative Results. ALS Association News (2010) Available at: http://www.alsa.org/news/archive/talampanel-trial-concluded.html (Accessed: 17th May 2010).
32. Aizawa, H. et al. Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation. J Clinical Neuroscience (2016 in press).
33. Mendez, E. F., Daley, E. L., Tang, X., Vidensky, S. & Sattler, R. Role of ADARB2 in GLUa2 editing deficiency in C9ORF72 amyotrophic lateral sclerosis and frontotemporal dementia. Abstract Society for Neuroscience 2015 69, 11 (2015).
34. Misawa, H. et al. VACHT-Cre. Fast and VACHT-Cre.Slow: postnatal expression of Cre recombinase in somatomotor neurons with different onset. Genesis 37, 44–50 (2003).

Acknowledgements
We thank Eisai Co., Ltd. for providing us with the perampanel reagent; Dr. Hui Lin Chai, Dr. Takashi Hosaka, Ms. Keiko Izumi and Mr. Naoki Inoue (Tokyo Univ.) for technical assistance; and Prof. Kazunori Kataoka and Assoc. Prof. Keiji Itaka (Tokyo Univ.) for kindly providing us with research facilities. This study was supported in part by an IBC Grant (Japan ALS Association) and by a grant-in-aid from Japan Intractable Disease Research Foundation.

Author Contributions
S.K. supervised the entire project. M.A., T.Y. and S.K. conceived and designed the experiments. M.A. and S.K. wrote the main text, and M.A., T.Y. and N.H. made the figures. M.A., T.Y., N.H. and S.T. conducted the experiments and analyzed the data. All of the co-authors (M.A., T.Y., N.H., S.T. and S.K.) discussed the results and commented on the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Akamatsu, M. et al. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep. 6, 28649; doi: 10.1038/srep28649 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/